AI in cancer care receives a significant boost as Outcomes4Me, a Boston-based company revolutionizing direct-to-patient platforms, raises $21 million to expand its global oncology innovation, deepen real-world data capabilities, strengthen clinical trial access, and improve patient empowerment worldwide.

Outcomes4Me continues to redefine AI in cancer care by merging technology with personalized medicine. With this new $21 million funding round led by UK-based Salica Investments, the company aims to push boundaries in global oncology innovation while maintaining a sharp focus on real-time clinical trial access and patient empowerment.

This funding will help us further enhance our platform, expand our reach, and drive meaningful revenue growth,” said Maya R Said, Sc.D., Founder and CEO of Outcomes4Me.

The platform combines updated clinical guidelines, genomics, symptom tracking, and trial matching in a user-friendly interface that empowers patients to take control of their journey from diagnosis by providing precise and actionable insights.

Outcomes4Me, Expanding Footprint and Data Depth

The new capital will enable Outcomes4Me to intensify its global direct-to-patient platform reach and extend services across multiple cancer types and geographies. In parallel, the company will enhance its proprietary real-world data sets and integrate deeper AI insights at the drug level—fueling even more personalized outcomes.

“AI will reshape cancer care, and this investment accelerates our ability to deliver personalized treatments and improved outcomes to patients at scale. With more than 280,000 cancer patients using our AI-enabled platform, we’re not just offering people diagnosed with cancer a tool, and we’re empowering them with intelligent, real-time insights that guide them through every step of their care,” Maya R Said added.

Currently, seven of the world’s ten leading cancer pharmaceutical firms already partner with the company, underscoring its leadership in AI in cancer care and its ability to deliver immediate value.

Scaling Partnerships for Global Impact

Outcomes4Me plans to scale collaborations with leading life sciences companies and health systems. By doing so, it will advance clinical trial access, boost revenue through innovative partnerships, and deepen its influence in the evolving digital health landscape.

Furthermore, the firm remains committed to outcomes-based research by harnessing real-world data to shape global standards in oncology innovation.

Founded and led by CEO Maya R. Said, Outcomes4Me remains dedicated to enabling smarter, faster, and more personalized decisions for patients. The company’s platform, centered on patient empowerment, is built for accessibility and clarity—removing ambiguity from a diagnosis that often overwhelms.

The $21 million round brings the total raised to $38 million, cementing the company’s position as a rising leader in AI for cancer care and a vital partner for the future of global health systems.

“Outcomes4Me is an AI-driven pioneer in the oncology space, scaling rapidly in a market that demands smarter, personalized healthcare solutions. We are excited to support their digital platform as part of our deep commitment to help advance oncology care and improve patient outcomes,” said Amy Summy, Executive Vice President of Labcorp.

Follow USTechTimes on Facebook, Twitter and Linkedin for in-depth news of market trends, funding updates, and regulatory changes affecting startups in USA.

We Recommend: